Efficacy and response time to sertraline versus fluoxetiae in the treatment of unipolar major depressive disorder

R. A. Suri, L. L. Altshuler, N. L. Rasgon, J. L. Calcagno, Mark A Frye, M. J. Gitlin, S. Hwang, J. Zuckerbrow-Miller

Research output: Contribution to journalArticle

24 Citations (Scopus)

Abstract

Background: Few studies have compared the treatment efficacy of the 2 selective serotonin reuptake inhibitors sertraline and fluoxetine. Method: A randomized, single-blind, parallelgroup study of 10 weeks' duration comparing the efficacy of sertraline, 50 mg/day; sertraline, 100 mg/day; and fluoxetine, 20 mg/day, was conducted in 44 psychiatric outpatients with DSM-IV unipolar major depressive disorder. Antidepressant dosages were doubled at 6 weeks for subjects who had not achieved remission. Primary outcome measurements included the 21-item Hamilton Rating Scale for Depression (HAM-D) and the Clinical Global Impressions-Improvement scale (CGI-I), with scores of ≤ 7 on the HAM-D and ≤ 2 on the CGI-I representing a positive treatment response, i.e., remission. Results: At 4 weeks, significant differences in rate of positive treatment response were noted, with 0% for sertraline, 50 mg; 46% for sertraline, 100 mg; and 31% for fluoxetine, 20 mg (p = .023). At 6 weeks, positive treatment response rates were 21%, 43%, and 31% for subjects taking 50 mg of sertraline, those taking 100 mg of sertraline, and those taking 20 mg of fluoxetine, respectively, with treatment groups no longer differing significantly from each other. In subjects for whom antidepressant dose was doubled at week 6, response rates at week 10 (4 weeks on increased dose) were 40% for sertraline, 100 mg; 43% for sertraline, 200 mg; and 55% for fluoxetine, 40 mg. Conclusion: Subjects taking sertraline, 100 mg, and fluoxetine, 20 mg, demonstrated an earlier treatment response compared with subjects taking sertraline, 50 mg. For patients without a positive response at 6 weeks, an increased antidepressant dose resulted in remission for a substantial proportion of patients when assessed 4 weeks later.

Original languageEnglish (US)
Pages (from-to)942-946
Number of pages5
JournalJournal of Clinical Psychiatry
Volume61
Issue number12
StatePublished - 2000
Externally publishedYes

Fingerprint

Sertraline
Major Depressive Disorder
Reaction Time
Fluoxetine
Therapeutics
Antidepressive Agents
Single-Blind Method
Serotonin Uptake Inhibitors
Diagnostic and Statistical Manual of Mental Disorders
Psychiatry
Outpatients

ASJC Scopus subject areas

  • Psychiatry and Mental health
  • Clinical Psychology

Cite this

Suri, R. A., Altshuler, L. L., Rasgon, N. L., Calcagno, J. L., Frye, M. A., Gitlin, M. J., ... Zuckerbrow-Miller, J. (2000). Efficacy and response time to sertraline versus fluoxetiae in the treatment of unipolar major depressive disorder. Journal of Clinical Psychiatry, 61(12), 942-946.

Efficacy and response time to sertraline versus fluoxetiae in the treatment of unipolar major depressive disorder. / Suri, R. A.; Altshuler, L. L.; Rasgon, N. L.; Calcagno, J. L.; Frye, Mark A; Gitlin, M. J.; Hwang, S.; Zuckerbrow-Miller, J.

In: Journal of Clinical Psychiatry, Vol. 61, No. 12, 2000, p. 942-946.

Research output: Contribution to journalArticle

Suri, RA, Altshuler, LL, Rasgon, NL, Calcagno, JL, Frye, MA, Gitlin, MJ, Hwang, S & Zuckerbrow-Miller, J 2000, 'Efficacy and response time to sertraline versus fluoxetiae in the treatment of unipolar major depressive disorder', Journal of Clinical Psychiatry, vol. 61, no. 12, pp. 942-946.
Suri, R. A. ; Altshuler, L. L. ; Rasgon, N. L. ; Calcagno, J. L. ; Frye, Mark A ; Gitlin, M. J. ; Hwang, S. ; Zuckerbrow-Miller, J. / Efficacy and response time to sertraline versus fluoxetiae in the treatment of unipolar major depressive disorder. In: Journal of Clinical Psychiatry. 2000 ; Vol. 61, No. 12. pp. 942-946.
@article{d429c42e04ce4ca8bed5f1136ac7153c,
title = "Efficacy and response time to sertraline versus fluoxetiae in the treatment of unipolar major depressive disorder",
abstract = "Background: Few studies have compared the treatment efficacy of the 2 selective serotonin reuptake inhibitors sertraline and fluoxetine. Method: A randomized, single-blind, parallelgroup study of 10 weeks' duration comparing the efficacy of sertraline, 50 mg/day; sertraline, 100 mg/day; and fluoxetine, 20 mg/day, was conducted in 44 psychiatric outpatients with DSM-IV unipolar major depressive disorder. Antidepressant dosages were doubled at 6 weeks for subjects who had not achieved remission. Primary outcome measurements included the 21-item Hamilton Rating Scale for Depression (HAM-D) and the Clinical Global Impressions-Improvement scale (CGI-I), with scores of ≤ 7 on the HAM-D and ≤ 2 on the CGI-I representing a positive treatment response, i.e., remission. Results: At 4 weeks, significant differences in rate of positive treatment response were noted, with 0{\%} for sertraline, 50 mg; 46{\%} for sertraline, 100 mg; and 31{\%} for fluoxetine, 20 mg (p = .023). At 6 weeks, positive treatment response rates were 21{\%}, 43{\%}, and 31{\%} for subjects taking 50 mg of sertraline, those taking 100 mg of sertraline, and those taking 20 mg of fluoxetine, respectively, with treatment groups no longer differing significantly from each other. In subjects for whom antidepressant dose was doubled at week 6, response rates at week 10 (4 weeks on increased dose) were 40{\%} for sertraline, 100 mg; 43{\%} for sertraline, 200 mg; and 55{\%} for fluoxetine, 40 mg. Conclusion: Subjects taking sertraline, 100 mg, and fluoxetine, 20 mg, demonstrated an earlier treatment response compared with subjects taking sertraline, 50 mg. For patients without a positive response at 6 weeks, an increased antidepressant dose resulted in remission for a substantial proportion of patients when assessed 4 weeks later.",
author = "Suri, {R. A.} and Altshuler, {L. L.} and Rasgon, {N. L.} and Calcagno, {J. L.} and Frye, {Mark A} and Gitlin, {M. J.} and S. Hwang and J. Zuckerbrow-Miller",
year = "2000",
language = "English (US)",
volume = "61",
pages = "942--946",
journal = "Journal of Clinical Psychiatry",
issn = "0160-6689",
publisher = "Physicians Postgraduate Press Inc.",
number = "12",

}

TY - JOUR

T1 - Efficacy and response time to sertraline versus fluoxetiae in the treatment of unipolar major depressive disorder

AU - Suri, R. A.

AU - Altshuler, L. L.

AU - Rasgon, N. L.

AU - Calcagno, J. L.

AU - Frye, Mark A

AU - Gitlin, M. J.

AU - Hwang, S.

AU - Zuckerbrow-Miller, J.

PY - 2000

Y1 - 2000

N2 - Background: Few studies have compared the treatment efficacy of the 2 selective serotonin reuptake inhibitors sertraline and fluoxetine. Method: A randomized, single-blind, parallelgroup study of 10 weeks' duration comparing the efficacy of sertraline, 50 mg/day; sertraline, 100 mg/day; and fluoxetine, 20 mg/day, was conducted in 44 psychiatric outpatients with DSM-IV unipolar major depressive disorder. Antidepressant dosages were doubled at 6 weeks for subjects who had not achieved remission. Primary outcome measurements included the 21-item Hamilton Rating Scale for Depression (HAM-D) and the Clinical Global Impressions-Improvement scale (CGI-I), with scores of ≤ 7 on the HAM-D and ≤ 2 on the CGI-I representing a positive treatment response, i.e., remission. Results: At 4 weeks, significant differences in rate of positive treatment response were noted, with 0% for sertraline, 50 mg; 46% for sertraline, 100 mg; and 31% for fluoxetine, 20 mg (p = .023). At 6 weeks, positive treatment response rates were 21%, 43%, and 31% for subjects taking 50 mg of sertraline, those taking 100 mg of sertraline, and those taking 20 mg of fluoxetine, respectively, with treatment groups no longer differing significantly from each other. In subjects for whom antidepressant dose was doubled at week 6, response rates at week 10 (4 weeks on increased dose) were 40% for sertraline, 100 mg; 43% for sertraline, 200 mg; and 55% for fluoxetine, 40 mg. Conclusion: Subjects taking sertraline, 100 mg, and fluoxetine, 20 mg, demonstrated an earlier treatment response compared with subjects taking sertraline, 50 mg. For patients without a positive response at 6 weeks, an increased antidepressant dose resulted in remission for a substantial proportion of patients when assessed 4 weeks later.

AB - Background: Few studies have compared the treatment efficacy of the 2 selective serotonin reuptake inhibitors sertraline and fluoxetine. Method: A randomized, single-blind, parallelgroup study of 10 weeks' duration comparing the efficacy of sertraline, 50 mg/day; sertraline, 100 mg/day; and fluoxetine, 20 mg/day, was conducted in 44 psychiatric outpatients with DSM-IV unipolar major depressive disorder. Antidepressant dosages were doubled at 6 weeks for subjects who had not achieved remission. Primary outcome measurements included the 21-item Hamilton Rating Scale for Depression (HAM-D) and the Clinical Global Impressions-Improvement scale (CGI-I), with scores of ≤ 7 on the HAM-D and ≤ 2 on the CGI-I representing a positive treatment response, i.e., remission. Results: At 4 weeks, significant differences in rate of positive treatment response were noted, with 0% for sertraline, 50 mg; 46% for sertraline, 100 mg; and 31% for fluoxetine, 20 mg (p = .023). At 6 weeks, positive treatment response rates were 21%, 43%, and 31% for subjects taking 50 mg of sertraline, those taking 100 mg of sertraline, and those taking 20 mg of fluoxetine, respectively, with treatment groups no longer differing significantly from each other. In subjects for whom antidepressant dose was doubled at week 6, response rates at week 10 (4 weeks on increased dose) were 40% for sertraline, 100 mg; 43% for sertraline, 200 mg; and 55% for fluoxetine, 40 mg. Conclusion: Subjects taking sertraline, 100 mg, and fluoxetine, 20 mg, demonstrated an earlier treatment response compared with subjects taking sertraline, 50 mg. For patients without a positive response at 6 weeks, an increased antidepressant dose resulted in remission for a substantial proportion of patients when assessed 4 weeks later.

UR - http://www.scopus.com/inward/record.url?scp=0034534194&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034534194&partnerID=8YFLogxK

M3 - Article

C2 - 11206600

AN - SCOPUS:0034534194

VL - 61

SP - 942

EP - 946

JO - Journal of Clinical Psychiatry

JF - Journal of Clinical Psychiatry

SN - 0160-6689

IS - 12

ER -